$88.4 Million is the total value of M28 Capital Management LP's 14 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WVE | Buy | WAVE LIFE SCIENCES LTD | $30,093,500 | -27.2% | 6,950,000 | +17.7% | 34.03% | -13.6% |
| RCKT | ROCKET PHARMACEUTICALS INC | $12,369,230 | -12.5% | 722,080 | 0.0% | 13.99% | +3.8% | |
| INVIVYD INC | $11,097,900 | -20.0% | 9,248,250 | 0.0% | 12.55% | -5.1% | ||
| TGTX | Buy | TG THERAPEUTICS INC | $5,106,080 | +313.4% | 339,500 | +225.2% | 5.77% | +390.5% |
| SWTX | Buy | SPRINGWORKS THERAPEUTICS INC | $5,088,798 | +78.0% | 197,700 | +79.9% | 5.75% | +111.2% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $5,051,926 | +58.2% | 304,700 | -27.3% | 5.71% | +87.7% |
| IONS | IONIS PHARMACEUTICALS INC | $4,513,962 | -5.4% | 126,300 | 0.0% | 5.10% | +12.2% | |
| STOK | Buy | STOKE THERAPEUTICS INC | $4,438,974 | -0.4% | 532,890 | +10.4% | 5.02% | +18.1% |
| PRQR | PROQR THRAPEUTICS N V | $4,069,578 | -42.4% | 1,910,600 | 0.0% | 4.60% | -31.7% | |
| CRIS | CURIS INC | $2,671,357 | +8.4% | 4,482,142 | 0.0% | 3.02% | +28.5% | |
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $1,711,960 | -70.7% | 67,400 | -53.2% | 1.94% | -65.2% |
| ATRA | ATARA BIOTHERAPEUTICS INC | $1,273,970 | -11.6% | 439,300 | 0.0% | 1.44% | +4.9% | |
| SLN | SILENCE THERAPEUTICS PLCads | $904,580 | -59.3% | 145,900 | 0.0% | 1.02% | -51.8% | |
| NEXI | NEXIMMUNE INC | $50,708 | +56.3% | 133,442 | 0.0% | 0.06% | +83.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 46.4% |
| INVIVYD INC | 8 | Q3 2023 | 32.1% |
| ROCKET PHARMACEUTICALS INC | 8 | Q3 2023 | 16.6% |
| BRIDGEBIO PHARMA INC | 8 | Q3 2023 | 6.1% |
| TG THERAPEUTICS INC | 8 | Q3 2023 | 9.2% |
| NEXIMMUNE INC | 8 | Q3 2023 | 0.5% |
| STOKE THERAPEUTICS INC | 7 | Q2 2023 | 10.2% |
| CURIS INC | 7 | Q2 2023 | 9.7% |
| PROQR THRAPEUTICS N V | 7 | Q3 2023 | 6.7% |
| ATARA BIOTHERAPEUTICS INC | 5 | Q1 2023 | 5.6% |
View M28 Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adagio Therapeutics, Inc. | August 19, 2022 | 9,248,250 | 8.5% |
View M28 Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| SC 13G/A | 2024-02-12 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-05-25 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-10 |
View M28 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.